Search results
Results from the WOW.Com Content Network
Oxford Nanopore Technologies plc is a UK-based company which develops and sells nanopore sequencing products (including the portable DNA sequencer, MinION) for the direct, electronic analysis of single molecules. [2] [3] [4] It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index. [5]
The London-listed firm, which was spun out from the University of Oxford and went public in 2021, expects full-year revenue to be 169 million pounds ($215.2 million), falling short of the ...
Oxford Nanopore Technologies: 2 November 2012 [315] Nanopore sequencing: United Kingdom Sword Health: 2 November 2021 [316] ... IPO 5 United States Peloton: 4.0
British technology company Oxford Nanopore said it hoped to reach break-even by the end of 2026, as it outlined plans to drive further growth in the life science research tools market and expand ...
In January, CG Oncology, a biotech, saw its shares nearly double from their $19 IPO price to $37.17 during their debut. Then, in the aftermarket, CG’s stock soared to a high of $47.93 in ...
Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California.Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function.
The IPO market saw a flurry of big listings in the last five weeks, emerging from an arid spell that lasted most of 2022 and 2023 and was driven by stock market volatility amid rising interest rates.
An initial public offering (IPO) or stock launch is a public offering in which shares of a company are sold to institutional investors [1] and usually also to retail (individual) investors. [2] An IPO is typically underwritten by one or more investment banks, who also arrange for the shares to be listed on one or more stock exchanges.